A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)
A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF PF-05280586 VERSUS RITUXIMAB FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH CD20-POSITIVE, LOW TUMOR BURDEN, FOLLICULAR LYMPHOMA
Sponsor: Pfizer
A PHASE3 clinical study on Follicular Lymphoma, this trial is completed. The trial is conducted by Pfizer and has accumulated 27 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
27 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jul 2019 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 22 earlier versions
-
Apr 2019 — Jul 2019 [monthly]
Completed PHASE3
-
Feb 2019 — Apr 2019 [monthly]
Completed PHASE3
-
Dec 2018 — Feb 2019 [monthly]
Completed PHASE3
-
Nov 2018 — Dec 2018 [monthly]
Completed PHASE3
-
Oct 2018 — Nov 2018 [monthly]
Completed PHASE3
-
Sep 2018 — Oct 2018 [monthly]
Completed PHASE3
-
Aug 2018 — Sep 2018 [monthly]
Completed PHASE3
-
Jul 2018 — Aug 2018 [monthly]
Completed PHASE3
-
Jun 2018 — Jul 2018 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Mar 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
-
Feb 2018 — Mar 2018 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Dec 2017 — Feb 2018 [monthly]
Recruiting PHASE3
-
Nov 2017 — Dec 2017 [monthly]
Recruiting PHASE3
-
Oct 2017 — Nov 2017 [monthly]
Recruiting PHASE3
-
Sep 2017 — Oct 2017 [monthly]
Recruiting PHASE3
-
Aug 2017 — Sep 2017 [monthly]
Recruiting PHASE3
-
Jun 2017 — Aug 2017 [monthly]
Recruiting PHASE3
-
May 2017 — Jun 2017 [monthly]
Recruiting PHASE3
-
Apr 2017 — May 2017 [monthly]
Recruiting PHASE3
-
Mar 2017 — Apr 2017 [monthly]
Recruiting PHASE3
-
Feb 2017 — Mar 2017 [monthly]
Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
Sep 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
A Coruña, Spain , Akita, Japan , Anaheim, United States , Ankara, Turkey (Türkiye) , Anyang-si, South Korea , Aravaca, Spain , Athens, Greece , Aurora, United States , Aydin, Turkey (Türkiye) , Baltimore, United States and 237 more locations